XML Print


Department of Pediatrics, Assam Medical College and Hospital, Dibrugarh, Assam, India
Abstract:   (3 Views)
Introduction: Stenotrophomonas maltophilia, a Gram-negative, multidrug-resistant bacterium, is an emerging cause of hospital-acquired infections, particularly in immunocompromised pediatric patients. Its resistance to multiple antibiotics complicates therapeutic management, contributing to significant morbidity and mortality. This case series examines the risk factors and management strategies for S. maltophilia infections in a Neonatal and Pediatric Intensive Care Unit (NICU/PICU). Methods: A retrospective case series was conducted involving four infants (aged 1–4 months) admitted to the NICU or PICU at a tertiary care hospital in upper Assam, India, from January to December 2023. Clinical data, risk factors, antibiotic susceptibility, treatments, and outcomes were analyzed with parental consent. Results: All patients presented with sepsis, three with pneumonia and two with suspected meningitis. Risk factors included prematurity (n=2), low birth weight (n=2), mechanical ventilation (n=2), and prior antibiotic exposure (n=4). Blood cultures confirmed S. maltophilia, resistant to empirical antibiotics (ciprofloxacin, gentamicin) but isolates were susceptible to levofloxacin (n=4) and minocycline (n=4); two were also susceptible to trimethoprim-sulfamethoxazole (TMP-SMX) (n=2). Treatment with levofloxacin (14–21 days; n=3) or oral TMP-SMX (10 days; n=1) resulted in recovery in three patients with minimal residual sequelae. One patient died post-discharge after being readmitted for severe respiratory distress; the definitive cause of death was unknown. Conclusion: Tailored antibiotic therapy guided by susceptibility testing was associated with improved outcomes in S. maltophilia infections, despite multidrug resistance. Prematurity and mechanical ventilation were identified as key risk factors, highlighting the need for infection control and judicious antibiotic use.
     
Type of Study: Case Report | Subject: Anti-microbial agents, resistance and treatment protocols
Received: 2024/04/12 | Accepted: 2025/09/10

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.